SG10201606278UA - Peptide - Google Patents

Peptide

Info

Publication number
SG10201606278UA
SG10201606278UA SG10201606278UA SG10201606278UA SG10201606278UA SG 10201606278U A SG10201606278U A SG 10201606278UA SG 10201606278U A SG10201606278U A SG 10201606278UA SG 10201606278U A SG10201606278U A SG 10201606278UA SG 10201606278U A SG10201606278U A SG 10201606278UA
Authority
SG
Singapore
Prior art keywords
peptide
Prior art date
Application number
SG10201606278UA
Inventor
Neil Deborah O
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB0418414.9A priority Critical patent/GB0418414D0/en
Priority to US7979505A priority
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Publication of SG10201606278UA publication Critical patent/SG10201606278UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723Cationic antimicrobial peptides, e.g. defensins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • C07K5/0817Tripeptides with the first amino acid being basic the first amino acid being Arg
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/398Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria
    • Y02A50/399Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria of the genus Borrellia
    • Y02A50/401Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria of the genus Borrellia the bacteria being Borrelia burgdorferi, i.e. Lyme disease or Lyme borreliosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/398Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria
    • Y02A50/402Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria of the genus Rickettsia, Orientia, Ehrlichia, Neorickettsia, Neoehrlichia or Anaplasma, i.e. Rickettsial diseases, e.g. spotted fever
    • Y02A50/406Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a bacteria of the genus Rickettsia, Orientia, Ehrlichia, Neorickettsia, Neoehrlichia or Anaplasma, i.e. Rickettsial diseases, e.g. spotted fever the bacteria being Yersinia pestis, i.e. Plague
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/409Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Leishmania i.e. Leishmaniasis, Sand-fly fever, phlebotomus fever, kala-azar, black fever or Dumdum fever
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/413Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Trypanosoma
    • Y02A50/414Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Trypanosoma the protozoa being Trypanosoma cruzi i.e. Chagas disease or American trypanosomiasis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/417Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a helminth, i.e. Helmanthiasis
    • Y02A50/423Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a helminth, i.e. Helmanthiasis the helminth being a trematode flatworm of the genus Schistosoma, i.e. Schistosomiasis or bilharziasis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/462The waterborne disease being caused by a virus
    • Y02A50/465The waterborne disease being caused by a virus the virus being the poliovirus, i.e. Poliomyelitis or Polio
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/469The waterborne disease being caused by a bacteria the bacteria being clostridium botulinum, i.e. Botulism
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/473The waterborne disease being caused by a bacteria the bacteria being Escherichia coli, i.e. E. coli Infection
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/475The waterborne disease being caused by a bacteria of the genus Shigella, i.e. Dysentery
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/481The waterborne disease being caused by a bacteria of the genus Salmonella, i.e. Salmonellosis
SG10201606278UA 2004-08-18 2005-08-18 Peptide SG10201606278UA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0418414.9A GB0418414D0 (en) 2004-08-18 2004-08-18 Peptide
US7979505A true 2005-03-14 2005-03-14

Publications (1)

Publication Number Publication Date
SG10201606278UA true SG10201606278UA (en) 2016-09-29

Family

ID=35907779

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201606278UA SG10201606278UA (en) 2004-08-18 2005-08-18 Peptide
SG2013007356A SG188092A1 (en) 2004-08-18 2005-08-18 Peptide
SG200905379-4A SG155211A1 (en) 2004-08-18 2005-08-18 Peptide

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG2013007356A SG188092A1 (en) 2004-08-18 2005-08-18 Peptide
SG200905379-4A SG155211A1 (en) 2004-08-18 2005-08-18 Peptide

Country Status (25)

Country Link
US (4) US7847059B2 (en)
EP (5) EP1927597B1 (en)
JP (1) JP5020078B2 (en)
KR (1) KR101234780B1 (en)
CN (3) CN103360485A (en)
AT (1) AT479704T (en)
AU (1) AU2005273638B2 (en)
BR (1) BRPI0514420A (en)
CA (2) CA2974538A1 (en)
CY (1) CY1113684T1 (en)
DE (1) DE602005023315D1 (en)
DK (2) DK1927597T3 (en)
ES (1) ES2613027T3 (en)
GB (1) GB2431404A (en)
HK (1) HK1105982A1 (en)
IL (2) IL180727A (en)
MX (1) MX2007002057A (en)
NO (1) NO342832B1 (en)
NZ (2) NZ584340A (en)
PL (1) PL1778720T3 (en)
PT (2) PT1778720E (en)
RU (1) RU2396273C2 (en)
SG (3) SG10201606278UA (en)
SI (1) SI1778720T1 (en)
WO (1) WO2006018652A2 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1838331A4 (en) 2004-12-15 2012-12-26 Univ Colorado Antimicrobial peptides and methods of use
KR101413746B1 (en) * 2005-12-22 2014-07-01 노바바이오틱스 리미티드 Cyclic antimicrobial peptides
US9181303B2 (en) 2005-12-22 2015-11-10 Novabiotics Limited Treatment of bacterial infections with cyclic antimicrobial peptides
AU2012203804B2 (en) * 2005-12-22 2014-10-16 Novabiotics Limited Cyclic antimicrobial peptides
GB0702021D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
GB0702022D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
GB0702020D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
PT2178549T (en) * 2007-07-26 2016-12-20 Revance Therapeutics Inc Antimicrobial peptide and compositions thereof
US20100150985A1 (en) * 2008-04-24 2010-06-17 George Just Dental Implant, Endodontic Instrument, and Dental Filling Material Coated with a Peptide-Based Antimicrobial and Methods of Using and Making the Same
GB0817121D0 (en) * 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
CA2739842A1 (en) * 2008-10-06 2010-04-15 The Regents Of The University Of Colorado, A Body Corporate Antimicrobial peptides and methods of use
CA2741691C (en) * 2008-11-05 2019-11-26 Ingrid Lea Dodge Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
US8303962B2 (en) 2009-01-06 2012-11-06 C3 Jian, Inc. Antibacterial and antifungal peptides
FR2941231B1 (en) * 2009-01-16 2016-04-01 Sederma Sa Novel peptides, compositions comprising them and cosmetic and dermo-pharmaceutical uses
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
EP2437770A4 (en) * 2009-06-05 2013-11-06 Univ Colorado Regents Antimicrobial peptides
JP5664992B2 (en) * 2009-08-26 2015-02-04 国立大学法人名古屋大学 Cell specific peptides and uses thereof
WO2011113604A1 (en) * 2010-03-17 2011-09-22 Universität Regensburg Peptides or antibodies which bind to melanoma inhibitory activity (mia) protein
CN102206250B (en) * 2010-03-29 2017-03-15 翔升科技股份有限公司 The antimicrobial peptide of low haemocytolysis, medical composition and its use
GB201016733D0 (en) 2010-10-05 2010-11-17 Novabiotics Ltd Compounds and their use
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
RU2449805C1 (en) 2011-01-27 2012-05-10 Общество С Ограниченной Ответственностью "Гармония" Peptide pharmaceutical composition, based drug for gastroduodenal diseases caused by helicobacter pylori, and method of using it
EP2683419B1 (en) 2011-03-11 2018-05-09 Vib Vzw Molecules and methods for inhibition and detection of proteins
DE102011077071A1 (en) * 2011-06-07 2012-12-13 Beiersdorf Ag Active substance combination useful as a deodorizing agent in cosmetic deodorants, and as active ingredient in anti-dandruff shampoos, comprises epsilon-polylysine and climbazole
KR101345333B1 (en) * 2011-12-30 2013-12-30 조선대학교산학협력단 Novel antibiotic and antimycotic peptide with four times repeated Lys and Trp residues and use therof
GB201204457D0 (en) * 2012-03-14 2012-04-25 Novabiotics Ltd Polypeptides and their use
WO2013142184A1 (en) 2012-03-19 2013-09-26 Yale University Antimicrobial compositions and methods
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US9662372B2 (en) 2013-02-20 2017-05-30 Biolog, Inc. Compositions and methods to inactivate and/or reduce production of microbial toxins
RU2683651C2 (en) * 2013-06-18 2019-04-01 Иван Дмитриевич Захаров Medicine for treatment of keraticonus and other degenerative diseases of cornea and pharmaceutical agents based thereon
GB201409451D0 (en) 2014-05-28 2014-07-09 Ipabc Ltd Antimicrobial preparations, methods for preparing the same and uses thereof to combat microorganisms
US20170119814A1 (en) * 2014-06-17 2017-05-04 Albert Einstein College Of Medicine, Inc. Therapeutic nanoparticles and methods thereof
GB201416727D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
US10485165B2 (en) * 2014-11-25 2019-11-26 Chervon (Hk) Limited Grass trimmer
CN104311627B (en) * 2014-10-29 2018-04-10 中山大学 A kind of synthetic method of antibacterial peptide and application
EP3106172A1 (en) * 2015-06-15 2016-12-21 B. Braun Melsungen AG Antimicrobial agents and their use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3703173A (en) 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (en) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen
EP0050271A1 (en) 1980-10-14 1982-04-28 Maschinenfabrik Rieter Ag Automatic changing device for the supply of roving packages to a spinning machine
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
US4635627A (en) 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4624251A (en) 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
EP0400372B1 (en) * 1989-05-30 1995-08-02 Siemens Aktiengesellschaft CMOS/ECL converter
CA2061862A1 (en) * 1991-03-04 1992-09-05 Jonathan Duvick Natural and synthetic proteins with inhibitory activity towards pathogenic microorganisms
JP3022615B2 (en) * 1991-03-13 2000-03-21 日清製粉株式会社 Method for producing ε- polylysine
JP3000490B2 (en) * 1991-04-08 2000-01-17 チッソ株式会社 Anti-ringworm fungus agent
US5486503A (en) * 1991-11-01 1996-01-23 The Trustees Of Boston University Anti-fungal histatin-based peptides
EP0752885B1 (en) 1992-09-25 2003-07-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
JP3655359B2 (en) * 1995-06-29 2005-06-02 株式会社サンコンタクトレンズ Composition for cleaning and disinfecting hydrous soft contact lenses
US5714577A (en) * 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
JPH11113779A (en) * 1997-10-14 1999-04-27 Asahi Chem Ind Co Ltd Sterile wet tissue
CN1347421A (en) * 1999-04-15 2002-05-01 伊莱利利公司 Antifungal agents isolated from pseudomonas syringae
US20020001582A1 (en) * 1999-04-21 2002-01-03 Charter Edward A. Methods and compositions for inhibiting microbial growth
JP2001264707A (en) * 2000-03-22 2001-09-26 Chisso Corp Disinfecting and preserving solution for contact lens
JP2002020320A (en) * 2000-06-30 2002-01-23 Santen Pharmaceut Co Ltd Antiseptic agent for eye drop
FR2811666B1 (en) * 2000-07-13 2005-04-01 Entomed S A Antifungal and / or antibacterial peptides, preparations thereof and compositions containing same
CN1336383A (en) * 2000-07-29 2002-02-20 中国科学院昆明动物研究所 Giant web bombinin and its prepn. and pharmaceutical application
US7033991B2 (en) * 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
AU2003231471A1 (en) * 2002-04-25 2003-11-10 Toagosei Co., Ltd. Antimicrobial polypeptide and utizliation thereof
JP4461727B2 (en) * 2003-07-18 2010-05-12 チッソ株式会社 External preparation composition
US20080193616A1 (en) * 2007-02-13 2008-08-14 The Coca-Cola Company Beverage compositions comprising polylysine and at least one weak acid

Also Published As

Publication number Publication date
NO342832B1 (en) 2018-08-13
CA2575058A1 (en) 2006-02-23
AU2005273638A1 (en) 2006-02-23
US20070244044A1 (en) 2007-10-18
CN103360485A (en) 2013-10-23
SG188092A1 (en) 2013-03-28
PT1778720E (en) 2010-11-29
KR101234780B1 (en) 2013-02-20
EP3141559A1 (en) 2017-03-15
HK1105982A1 (en) 2011-02-18
PL1778720T3 (en) 2011-03-31
CY1113684T1 (en) 2016-06-22
GB0703060D0 (en) 2007-03-28
NZ553494A (en) 2010-07-30
IL180727D0 (en) 2007-06-03
US20110269673A1 (en) 2011-11-03
GB2431404A (en) 2007-04-25
CN101031583B (en) 2013-06-05
SI1778720T1 (en) 2011-04-29
WO2006018652A3 (en) 2006-07-13
EP1927597B1 (en) 2016-11-02
US20120071398A1 (en) 2012-03-22
CN103360486A (en) 2013-10-23
DK1927597T3 (en) 2017-02-13
IL213319D0 (en) 2011-07-31
ES2613027T3 (en) 2017-05-22
US8350003B2 (en) 2013-01-08
NO20071369L (en) 2007-05-04
PT1927597T (en) 2017-02-10
WO2006018652A2 (en) 2006-02-23
EP1778720B1 (en) 2010-09-01
CN101031583A (en) 2007-09-05
NZ584340A (en) 2010-09-30
RU2396273C2 (en) 2010-08-10
DE602005023315D1 (en) 2010-10-14
MX2007002057A (en) 2007-07-19
IL180727A (en) 2015-06-30
BRPI0514420A (en) 2008-06-10
EP3147293A1 (en) 2017-03-29
US8470769B2 (en) 2013-06-25
AT479704T (en) 2010-09-15
US20110021415A1 (en) 2011-01-27
IL213319A (en) 2017-07-31
RU2007109518A (en) 2008-09-27
DK1778720T3 (en) 2010-11-29
KR20070083486A (en) 2007-08-24
US8088888B2 (en) 2012-01-03
CA2974538A1 (en) 2006-02-23
AU2005273638B2 (en) 2011-09-29
CA2575058C (en) 2017-09-12
US7847059B2 (en) 2010-12-07
EP2096118A1 (en) 2009-09-02
EP1927597A1 (en) 2008-06-04
SG155211A1 (en) 2009-09-30
JP2008509980A (en) 2008-04-03
JP5020078B2 (en) 2012-09-05
EP1778720A2 (en) 2007-05-02

Similar Documents

Publication Publication Date Title
TWI346544B (en) Knochenschraube
GB0426736D0 (en) MyFone
SI1802198T1 (en) Synergistische fungizide Zusammensetzungen
DE602005003960D1 (en) Oximesther-fotoinitiatoren
DE602005017576D1 (en) Wirbel-osteosynthese-gerät
GB0622477D0 (en) Microprocessor architecture
DE602005025924D1 (en) Royl-coa-desaturase
EP1769743A4 (en) Radiotomograph
IL178884A (en) Cis-imidazolines
DE602005003667D1 (en) Sandwich-hybridmontagematte
DE602005022165D1 (en) Fluidleitungsverbindervorrichtung
DE602005025220D1 (en) Thernet-kabel
DE602005020252D1 (en) Röhrenförmige prothese
IL241732A (en) 2-di-tert-butyloxycarbonylamino-6-bromo-9-(2-trimehylsilylethoxy)methyl-9h-purine
PT1927597T (en) Antibacterial peptides
GB0405637D0 (en) Protein
DE502005007844D1 (en) Phasenstabile polyurethanprepolymere
TWI346750B (en) Planetenradgetriebe
DE602005007474D1 (en) Substituierte morpholin- und thiomorpholinderivate
SI2251330T1 (en) 4-Hydroxybenzomorphans
PL1593299T3 (en) Rotobaler
DE602005010905D1 (en) Roboterhandvorrichtung
ZA200700942B (en) Compressor-distractor
DE602005018033D1 (en) Luftreinigungsvorrichtung
ZA200609012B (en) 4-phenylamino-quinazolin-6-yl-amides